Company Overview of FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically-driven diseases. The company’s drug discovery engine deploys screening and structure-based approaches across various families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. It has a strategic partnership with Celgene Corporation. FORMA Therapeutics, Inc. was formerly known as Forma Pharmaceuticals, Inc. and changed its name to FORMA Therapeutics, Inc. in February 2008. The company was incorporated in 2007 and is based in Watertown, Massachusetts. The company has an additional chemistry operation in Branford, Connecticut. FORMA Therapeutics, ...
500 Arsenal Street
Watertown, MA 02472
Founded in 2007
Key Executives for FORMA Therapeutics, Inc.
Founder, Chief Executive Officer, President and Director
President of Research & Development
Head of Biomolecular Screening and Executive Director
Executive Vice President and Head of FORMA Therapeutics Ventures
Compensation as of Fiscal Year 2017.
FORMA Therapeutics, Inc. Key Developments
Celgene Corporation Exercises Option to Extend Strategic Collaboration Scope and Term with Forma Therapeutics
Aug 29 17
FORMA Therapeutics announced that Celgene Corporation has exercised its option, pursuant to the 2014 collaboration arrangement, to extend its strategic collaboration with FORMA by entering into a second collaboration agreement to evaluate additional therapeutic candidates across important emerging target families in the areas of protein homeostasis, inflammation & immunology, and neurodegeneration. Upon execution of this agreement, FORMA received an upfront cash payment of $195 million and Celgene was granted an option to license ex-U.S. rights to select current and future drug candidates through October 1, 2019. Celgene will assume responsibility for all global development activities and costs for in-licensed drug candidates after completion of Phase 1 clinical trials. Under the agreement, FORMA will be eligible to receive milestone payments for licensed drug candidates if certain development, regulatory and sales milestones are achieved. FORMA retains U.S. rights to all such licensed assets, including responsibility for manufacturing and commercialization in their territory. For products not licensed to Celgene, FORMA will maintain worldwide rights. In addition, also pursuant to the 2014 collaboration arrangement, Celgene retains the option to enter into one additional collaboration agreement, during which Celgene will have the exclusive option to acquire FORM, including the U.S. rights to all Celgene-licensed programs, and worldwide rights to other unencumbered, wholly-owned programs within FORMA at that time.
Forma Therapeutics, Inc Enters into an Agreement with Celgene Corporation
Apr 12 17
Forma Therapeutics, Inc. has entered into an agreement with Celgene Corporation, to advance innovative drugs trageting protein homeostasis. Pursuant to the agreement, Forma Therapeutics and Celgene added two additional objectives; which Forma Therapeutics received a two payments from Celgene. Under the agreement, Forma Therapeutics will discover compounds through its drug discovery team. Celgene will evaluate selected targets and lead assets in protein homeostasis pathways during the pre-clinical phase. Based on such evaluation, Celgene will have the right to obtain exclusive licenses with respect to the development and commercialization of multiple drug candidates outside of the US, in exchange for research and early development payments of up to USD 200 million to Forma Therapeutics. Under the terms, Forma Therapeutics is incentivized to advance the full complement of drug candidates through Phase I, while Celgene will be responsible for all further global clinical development for each licensed candidate. Forma Therapeutics is eligible to receive USD 315 million in potential payments based upon development, regulatory and sales objectives for the first ex-US License. Forma Therapeutics is also eligible to receive potential payments for successive licenses, which escalate for productivity increasing up to a maximum of USD 430 million per program. The partnership enables Forma Therapeutics and Celgene to bring new drugs against new targets and address unmet medical needs in the treatment of many cancers.
FORMA Therapeutics, Inc. Presents at East/West CEO Conference, Jan-08-2017 01:30 PM
Nov 30 16
FORMA Therapeutics, Inc. Presents at East/West CEO Conference, Jan-08-2017 01:30 PM. Venue: Four Seasons Hotel, 757 Market St, San Francisco, CA 94103, United States. Speakers: Steven Tregay, Co-Founder, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|